Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On July 27, 2022, Artemis Therapeutics, Inc. (the "Company") entered into a service agreement with the Company's Chief Financial Officer, Mr. David Dana (the "Service Agreement").

According to the Service Agreement, for his services as Chief Financial Officer, Mr. Dana will receive a monthly salary in the amount of NIS 10,000 plus VAT. In addition, the Company will grant Mr. Dana options to purchase 370,014 shares of common stock of the Company. The exercise price per share shall be $0.0624, reflecting a Company valuation of $7 million. The options will vest over a period of 36 months commencing on April 1, 2022 (the "Start Date"), with one third (1/3) of the total number of options vesting on the first anniversary of the Start Date (the "Cliff Date") and one twelfth (1/12) of the options vesting every three months following the Cliff Date.

The Service Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein. The foregoing is only a description of the material terms of the Service Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibit.

Item 9.01. Financial Statements and Exhibits.





              (d) Exhibits

Exhibit No.   Description
  10.1          Service Agreement, dated as of July 26, 2022, by and between the
              Company and David Dana.
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses